Charles Borum, MD
Family Practice · Natchez, MSNPI 1417042979
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 113 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $806 and has fallen 66.6% since, to $269 in 2025. Among family practice clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$479
- Merck$317
- AbbVie$196
- Lilly USA, LLC$165
- Novo Nordisk$151
- GSK$122
- plus $881 from 20 others
What the payments were for
- Food & beverage$2,311100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 25 | $479 |
| Merck | 14 | $317 |
| AbbVie(2 entities) | 7 | $196 |
| Lilly USA, LLC | 11 | $165 |
| Novo Nordisk | 10 | $151 |
| GSK | 4 | $122 |
| Boehringer Ingelheim | 4 | $100 |
| AstraZeneca | 4 | $95 |
| Phathom Pharmaceuticals, Inc. | 1 | $83 |
| Fidia Pharma USA Inc. | 6 | $72 |
| Amgen | 2 | $69 |
| Avanir Pharmaceuticals, Inc. | 4 | $63 |
| Abbott | 3 | $63 |
| Pfizer | 4 | $56 |
| Acadia Pharmaceuticals Inc | 2 | $52 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $31 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| SK Life Science, Inc. | 1 | $23 |
| Abiomed | 1 | $22 |
| Exact Sciences | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $13 |
How this compares
$2,311 in reported general payments places this provider in the 95th percentile of 36 family practice providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 128 | $167,161 |
| EliquisApixaban | 317 | $115,799 |
| JardianceEmpagliflozin | 94 | $74,556 |
| XareltoRivaroxaban | 222 | $72,887 |
| TrulicityDulaglutide | 86 | $63,388 |
| LinzessLinaclotide | 89 | $61,422 |
| MounjaroTirzepatide | 29 | $51,808 |
| Dupixent PenDupilumab | 13 | $51,331 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $46,890 |
| EntrestoSacubitril/Valsartan | 87 | $38,485 |
| FarxigaDapagliflozin Propanediol | 76 | $32,985 |
| JanuviaSitagliptin Phosphate | 40 | $21,500 |
| Potassium Chloride | 623 | $16,812 |
| Memantine Hcl | 315 | $14,945 |
| Rivastigmine | 73 | $12,433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $151 | $167,161128 claims |
| PfizerEliquis | $56 | $115,799317 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $165 | $115,196115 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $100 | $80,104105 claims |
| Johnson & JohnsonXarelto | $479 | $72,887222 claims |
| AbbVieLinzess | $196 | $61,42289 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $122 | $51,73474 claims |
| AstraZenecaFarxiga, Brilinta | $95 | $40,81492 claims |
| MerckJanuvia, Janumet Xr | $317 | $27,16355 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 36 family practice providers in Mississippi.
Other family practice in Natchez
- Matthew VerucchiNatchez$0
- Robert DaleAmory$780
- Luke CampbellTupelo$482
- Joe PulliamGreenville$423
- Justin DukeTupelo$353
- Carla ArmstrongTylertown$344
- Ashley AlphonseJackson$194
- Sharon CollinsTylertown$111
- Chinedu IfejiagwaJackson$44
- Christian BeebeChoctaw$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.